Study: Fianlimab With Cemiplimab Combination Shows High Response Rate in Certain Patients With Advanced Melanoma
Source: Pharmacy Times, September 2022
New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.
An investigational combination of fianlimab, a LAG-3 inhibitor, and cemiplimab (Libtayo; Regeneron Pharmaceuticals, Inc), a PD-1 inhibitor, showed positive data in a phase 1 trial among patients with advanced melanoma. The results were presented at the European Society for Medical Oncology Congress 2022.
The objective response rate (ORR) was high in more than half of participants administered the combination of fianlimab and cemiplimab and who were not previously treated with a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.